poisar

Stocks · News reference

BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets

Fiscal.ai

BioCryst Pharmaceuticals received U.S. FDA approval for its new 150 mg oral pellet formulation of ORLADEYO (berotralstat) for the prevention of hereditary angioedema (HAE) attacks.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — BIOCRYST PHARMACEUTICALS INC (BCRX)

    Filed: 2026-11-04 AccNo: 0001171843-26-007097 Size: 451 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits